The company maintained a competitive ARPOB while steadily improving occupancy, driven by higher patient volumes and efficient capacity utilization
N17350 is the company’s first-in-class tumor-directed therapeutic, designed to harness the ELANE pathway
The findings, based on an exploratory analysis, indicate that CD47 expression may predict which patients benefit most from the therapy
The study tested whether PF’3944 could maintain efficacy when switching from weekly to monthly injections and remain safe and well-tolerated
As CRISPR and prime editing applications advance, researchers increasingly rely on longer guide RNAs to boost editing efficiency and reduce off-target effects
The new service delivers end-to-end support, managing every stage of an epigenomics project
A PRV is a tradable voucher granted by the FDA to encourage the development of new treatments for rare pediatric diseases
This achievement validates global demand and catapults Wanbury into high-growth acceleration
Glucon-D maintained its leadership position with a 59% MAT market share
Subscribe To Our Newsletter & Stay Updated
